What can be done for patients with NSCLC without druggable targets?

Benjamin Besse; Fabrice Andre; Jean Charles Soria

doi:10.1016/S1470-2045(13)70018-4

What can be done for patients with NSCLC without druggable targets?

Benjamin Besse, Fabrice Andre, Jean Charles Soria

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	191-192
Nombre de pages	2
journal	The Lancet Oncology
Volume	14
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/S1470-2045(13)70018-4
état	Publié - 1 mars 2013

Accès au document

10.1016/S1470-2045(13)70018-4

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{c85bc7d0bc5c4f53a52e949625b50066,

title = "What can be done for patients with NSCLC without druggable targets?",

author = "Benjamin Besse and Fabrice Andre and Soria, {Jean Charles}",

note = "Funding Information: BB has received research grants from Roche, Pfizer, Lilly, and Aventis. FA has served as a consultant for Novartis, AstraZeneca, and Roche, and has received honoraria from Novartis. J-CS has served as a consultant for Genentech, AstraZeneca, and Lilly, and holds a patent on ERCC1 as a predictive marker of response to chemotherapy (EP06290407.3).",

year = "2013",

month = mar,

day = "1",

doi = "10.1016/S1470-2045(13)70018-4",

language = "English",

volume = "14",

pages = "191--192",

journal = "The Lancet Oncology",